DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair,With death on the horizon, This will not stop me, Gods call only..........DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution

History and mission

NITD was founded in 2002 as a public-private partnership between Swiss-based pharmaceutical company Novartis and the Singapore Economic Development Board.[1]
NITD states its goals are "to discover novel treatments and prevention methods for major tropical diseases." Their website states they hope to have at least two drug candidates going through clinical trials in patients by the year 2012.[2]
Novartis has also stated that the NITD will seek to make treatments
developed by the NITD available without profit to the poor in developing
nations in which these diseases are endemic.[3]

Research

NITD's research model relies on global partnership with other research institutes.[1] In 2008, NITD announced a 5-year collaborative research effort would be conducted in cooperation with the TB Alliance to develop new medicines for tuberculosis, including drug resistant tuberculosis.[4]

Fighting neglected infectious diseases

The Novartis Institute for Tropical Diseases (NITD), one of
the institutes of the Novartis Institutes for BioMedical Research
(NIBR), is dedicated to finding new medicines to treat neglected,
infectious diseases. As a small-molecule drug discovery research
institute, it combines the drug-discovery expertise and cutting-edge
technologies of Novartis to fight infectious tropical diseases,
including Dengue fever, Human African Trypanomiasis and Malaria among
others.
In developing countries where these diseases are endemic,
Novartis will make treatments accessible to the communities that need
them. NITD was set up as a public-private partnership between Novartis
and the Singapore Economic Development Board (EDB) in 2002. Since then,
it has grown to more than 100 researchers and supporting staff. As a
major center of excellence for drug discovery, NITD will offer
exceptional teaching and training opportunities for post-doctoral
fellows and graduate students.Contact NITD
Novartis Institute for Tropical Diseases Pte. Ltd.
10 Biopolis Road
#05-01 Chromos
Singapore 138670

EARLIER

Research Scientist II

Exelixis Inc

June 2003 – February 2007 (3 years 9 months) • Team member of phosphatidylinositol-3 kinase (PI3K) project that lead
to a development candidate (XL765) currently in Phase Ib/2 trials.
• Design and synthesis of kinase inhibitors for use as anti-cancer agents
• Supervised an associate research scientist

The Scripps Research Institute

PostDoc, Chemistry

2001 – 2003

Synthesis and screening of a library of DNA binding agents based on analogs of distamycin A
Preparation of heterocyclic monomer building blocks for a library of DNA binding agents
Synthesis of isochrysohermidin-distamycin hybrids as new DNA binding agents

University of Illinois at Urbana-Champaign

Ph.D, Chemistry

University of Hawaii at Manoa

B.S., Chemistry

References

"Commitment to Patients Earns Novartis' Dr. Daniel Vasella B'nai B'rith International's Highest Award". PharmaLive. Canon Communications Pharmaceutical Media Group. 2008-12-15. Retrieved 2008-12-23. Novartis
has developed several programs aimed at enhancing affordability and
access to treatment, including the Novartis Institute for Tropical
Diseases, where Novartis researches novel treatments and prevention
methods for neglected tropical diseases such as Dengue fever, and will
make these available, without profit, to poor endemic countries.

"Novartis symposium in Mozambique tackles emerging tuberculosis challenges" (media release). Basel, Switzerland: Novartis Global Communications. 2008-09-08. p. 5. Retrieved 2008-12-23. One
of the core missions of the NITD is its commitment to improving access
to medicines and helping reduce the overall global TB disease burden.
The NITD recently announced a five-year research collaboration with the
TB Alliance to develop new medicines for TB, including drug-resistant
strains.

External links

Patents by Inventor Bryan K. S. Yeung

Abstract: The present
invention provides compounds of formula I: or a pharmaceutically
acceptable salt, tautomer, or stereoisomer, thereof, wherein the
variables are as defined herein. The present invention further provides
pharmaceutical compositions comprising such compounds and methods of
using such compounds for treating, preventing, inhibiting, ameliorating,
or eradicating the pathology and/or symptomology of a disease caused by
a Plasmodium parasite, such as malaria.

Abstract: The present
invention provides compounds for modulating protein kinase enzymatic
activity for modulating cellular activities such as proliferation,
differentiation, programmed cell death, migration and chemoinvasion.
Compounds of the invention inhibit, regulate and/or modulate kinases.
Methods of using the compounds and pharmaceutical compositions thereof
to treat kinase-dependent diseases and conditions are also an aspect of
the invention.

Abstract: The invention
relates to organic compounds which have interesting pharmaceutical
properties. In particular, the compounds are useful in the treatment
and/or prevention of infections such as those caused by Plasmodium
falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale,
Trypanosoma cruzi and parasites of the Leishmania genus such as, for
example. Leishmania donovani. The invention also relates to
pharmaceutical compositions containing the compounds, as well as
processes for their preparation.

Abstract: The invention
relates to organic compounds which have interesting pharmaceutical
properties. In particular, the compounds are useful in the treatment
and/or prevention of infections such as those caused by Plasmodium
falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale,
Trypanosoma cruzi and parasites of the Leishmania genus such as, for
example. Leishmania donovani. The invention also relates to
pharmaceutical compositions containing the compounds, as well as
processes for their preparation.

Abstract: The invention is
directed to a Compound of Formula I, II, or III. The invention provides
compounds that inhibit, regulate, and/or modulate PI3K that are useful
in the treatment of hyperproliferatives diseases, such as cancer.

Abstract: The invention
relates to organic compounds which have interesting pharmaceutical
properties. In particular, the compounds are useful in the treatment
and/or prevention of infections such as those caused by Plasmodium
falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale,
Trypanosoma cruzi and parasites of the Leishmania genus such as, for
example, Leishmania donovani. The invention also relates to
pharmaceutical compositions containing the compounds, as well as
processes for their preparation.

OCS......Facebook Badge

GCI..Facebook Badge

NDA...Facebook Badge

Adefmark

Animation

add to any 1

ADDTOANY

ADD THIS

MAVEN

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with GLENMARK PHARMACEUTICALS LTD, Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India.

Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him worlddrugtracker.

He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc.

He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, he has 9 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 20 Lakh plus views on dozen plus blogs, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto

He lives and will die for his family, 90% paralysis cannot kill his soul. Notably he has 9.5 lakh views on New Drug Approvals Blog in 211 countries..................click here

He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc

OLD BIO

DR ANTHONY MELVIN CRASTO Ph.D , Born in Mumbai in 1964 and graduated from Mumbai University, Completed his PhD from ICT ,1991, Mumbai, India in Organic chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues,

Currently he is working with GLENMARKPHARMA LTD, Research centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India.

Prior to joining Glenmark, he worked with major multinationals like Hoechst Marion Roussel, now Sanofi Aventis, & Searle India ltd, now RPG lifesciences, etc. He has worked in Basic research, Neutraceuticals, Natural products, Flavors, Fragrances, Pheromones, Vet Drugs, Drugs, formulation, GMP etc. He has total 29 yrs exp in this field, he is now helping millions, has million hits on google on all organic chemistry websites.

He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 25 year tenure, good knowledge of IPM, GMP, Regulatory aspects, he has several international drug patents published worldwide .

He suffered a paralytic stroke in dec 2007 and is bound to a wheelchair, this seems to have injected feul in him to help chemists around the world, he is more active than before and is pushing boundaries, he has one lakh connections on all networking sites, He makes himself available to all, contact him on +91 9323115463, amcrasto@gmail.com, Twitter @amcrasto